The era of advanced therapeutics for pediatric atopic dermatitis – can early systemic intervention reduce the type 2 inflammatory response and modify the atopic march?

Vroman F, de Graaf M.  Curr Opin Pediatr. 2026 May 7. doi: 10.1097/MOP.0000000000001576. 

Abstract

Purpose of review 

This figure demonstrateds the concept of disease modification
in pediatric atopic dermatitis showing the window of opportunity for
early systemic intervention to modify/attenuate the atopic march.

The recent development of advanced systemic treatment options for pediatric atopic dermatitis (AD) means that achieving long-term, off-therapy remission, so-called disease modification, has become a subject of discussion. Emerging evidence suggests that early intervention during a potential ‘window of opportunity’ could alter the natural course of AD. If such a window could be identified, early and targeted treatment might induce long-term disease remission and might reduce the risk of the development of highly burdensome atopic comorbidities.

Recent findings 

Among currently available therapies, dupilumab, targeting interleukin (IL)-4 and IL-13 signaling, provides the most compelling evidence for potential disease modification.

Studies indicate that a subset of patients treated with dupilumab may achieve prolonged remission after treatment discontinuation, and that treatment may reduce the risk of subsequent allergic disease development.

Summary 

Disease modification and long-term remission are no longer an idle hope for AD patients. However, translating this into clinical practice remains challenging due to the heterogeneity of AD and the lack of consensus of definitions. Future research should therefore focus on establishing these definitions, and on determining whether early systemic intervention can truly modify the disease itself and the atopic march.

KEY POINTS

• Atopic dermatitis is a highly burdensome disease which is often considered to be the first manifestation of the atopic march.
• Early therapeutic intervention could lead to long-term disease remission and attenuate the progression of the atopic march, a concept commonly referred to as disease modification.
• Dupilumab, which blocks interleukin (IL)-4 and IL-13 signaling, has shown some promising results regarding disease modification in a subgroup of patients.
• Future studies should further investigate the possibility of disease modification and the so-called ‘window of opportunity’ with regard to different systemic treatment options.

PDF